Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec;27(12):1841-1848.
doi: 10.1007/s10147-022-02241-6. Epub 2022 Oct 14.

Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302

Takashi Kasai  1 , Kiyoshi Mori  2 , Tomohide Sugiyama  3 , Nobuyuki Koyama  4 , Yoichi Nakamura  3 , Fumiyoshi Ohyanagi  5 , Hiroki Fukuda  6 , Eishin Hoshi  7 , Kunihiko Kobayashi  8 , Mitsuo Nakayama  6
Affiliations
Clinical Trial

Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302

Takashi Kasai et al. Int J Clin Oncol. 2022 Dec.

Abstract

Background: Nedaplatin and nab-paclitaxel are each efficacious in the treatment of squamous cell lung cancer.

Patients and methods: Eligibility criteria were: no prior chemotherapy, advanced squamous cell lung cancer; performance status 0-1, age > 20 years but < 75 years, and adequate hematologic, hepatic and renal function. Patients received escalating doses of nab-paclitaxel under a fixed dose of nedaplatin (100 mg/m2, day 1) every 3 weeks in phase I. The initial nab-paclitaxel dose was 100 mg/m2 on days 1 and 8 (level 1), and the next dose was 100 mg/m2 on days 1, 8, and 15 (level 2). In phase II, patients received the recommended doses. The primary endpoint was tumor response rate.

Results: In phase I, three patients at level 1 experienced no dose-limiting toxicities (DLTs) and two patients at level 2 experienced DLTs. Level 1 was thus determined as the recommended dose. Twenty-three patients were enrolled in phase II. The 3 patients in level 1 and 23 patients in phase II were included together for analyses. Three of these 26 patients were excluded from response analysis due to pneumonia and patient refusal. Response rate was 91.3% (95% confidence interval, 72.0-98.9%). Toxicities observed during all cycles were tolerable.

Conclusions: The recommended dose for this combination was nedaplatin at 100 mg/m2 on day 1 and nab-paclitaxel at 100 mg/m2 on days 1 and 8 every 3 weeks. The combination of nedaplatin and nab-paclitaxel appears safe and efficacious in patients with untreated advanced squamous cell lung cancer.

Keywords: Nab-paclitaxel; Nedaplatin; Phase I/II study; Platinum compound; Squamous cell lung cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30 - DOI - PubMed
    1. Mokdad AH, Dwyer-Lindgren L, Fitzmaurice C et al (2017) Trends and patterns of disparities in cancer mortality among US counties, 1980–2014. JAMA 24:388–406 - DOI
    1. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866–1872 - DOI - PubMed
    1. Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342:19–21 - DOI - PubMed
    1. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899–909 - DOI

Publication types

MeSH terms

LinkOut - more resources